Whooping cough vaccine safety under the microscope in thailand
NCT ID NCT07400120
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at the safety of the VacPertagen whooping cough vaccine in over 5,400 people in Thailand, including pregnant women and their newborns. Healthcare workers reported any side effects after vaccination using standard forms. The goal was to catch any unexpected safety issues in a real-world setting beyond the initial trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- VacPertagen (recombinant acellular pertussis vaccine)
- What this could lead to
- If the results confirm a good safety profile, this could support continued use of VacPertagen to protect against whooping cough in a broader population.
- What could go wrong
- This is an observational safety study, not a test of how well the vaccine works. It cannot prove effectiveness, and rare side effects may still be missed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
5,414 people
The number who actually took part.
- Started
-
Jul 2018
- Finished
-
Feb 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of a cohort of HCPs working in private and government hospitals and clinics in central, eastern, northern and southern Thailand where VacPertagen vaccine is marketed. An HCP is defined as medically qualified person, such as physician, nurse or pharmacist.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: An HCP will be eligible for inclusion if ALL of the following criteria are met at the time of screening: 1. Has prescribed and/or administered VacPertagen to adults and adolescents in accordance with current national immunization guidelines. 2. Employed full-or part-time (\> 8 hours/week) in a government or private hospital or medical clinic. 3. Available for follow-up by telephone call, email or site visit if there are missing information in the study questionnaire, to confirm the occurrence or clarify the nature of an adverse event following immunization with VacPertagen. 4. Willing and able to comply with the study procedures. Exclusion Criteria: * Unwilling to take part in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pertussis (whooping cough) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BioNet-Asia Co.,Ltd.
Bangkok, Bangkok, 10260, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine trial aims to shield teens and adults from whooping cough
- Thousands monitored: is the whooping cough vaccine safe in real life?
- Scientists deliberately infect volunteers with whooping cough to speed up vaccine research
- Massive U.S. study to see if whooping cough vaccine is safe for pregnant women and babies
- New whooping cough vaccine shows promise for toddlers
- Whooping cough vaccine safety checked in 2,700 thai moms and babies